| セッション情報 | パネルディスカッション8(肝臓学会・消化器病学会合同)東アジアにおける肝疾患の問題点と治療の特色 |
|---|---|
| タイトル | 肝PD8-4指：Liver diseases. what is being done in Indonesia? |
| 演者 | T. Utsumi（Indonesia-Japan Collaborative Research Center for Emerging and Re-emerging Infectious Diseases, Institute of Tropical Disease, Airlangga UniversityDELIMITERCenter for Infectious Diseases, Graduate School of Medicine, Kobe University） |
| 共同演者 | |
| 抄録 | Indonesia is a multiethnic country and its population is around 240 million. There are 20 million individuals with chronic liver disease (CLD) in Indonesia, and approximately 20-40% of them progress to liver cirrhosis. Nation-wide data shows the prevalence of HBsAg is 2-10% with highest prevalence at the age of 45-49 years. The prevalence of anti-HCV is 3% with highest prevalence at the age of 55-56 years. The most common HBV genotype is genotype B3. Telbivudine, Lamivudin and Pegylated interferon are only available for the treatment of chronic hepatitis B. As for Entecavir, it is also available but sometimes it is difficult to obtain. The most common HCV genotype is genotype 1b. Pegylated interferon alpha 2a and ribavirin combination therapy is the standard therapy for chronic hepatitis C. Therapy for Hepatitis B and C is covered by government insurance only for government employees, while only some private insurance covers for hepatitis B and/or C treatment. Thus, medical insurance remains insufficient and only 20% of individuals with CLD can receive appropriate treatment. On the other hand, Indonesian government is promoting universal hepatitis B vaccination program since 1977, as a cost effective method to prevent CLD. The possible strategy for controlling liver disease in Indonesia will be discussed. |
| 索引用語 | Indonesia, struggle for management |